Introduction
Pathogenic microorganisms have evolved mechanisms to evade complement attack (reviewed in reference 1). In gram negative enteric bacteria, such as Salmonellae, the presence of a confluent lipopolysaccharide (LPS)l layer within the outer membrane is associated with complement resistance. In addition, wild type (smooth) LPS masks cognate epitopes on the outer membrane for cell surface phagocyte adhesion molecules, outer membrane-specific bacteriophages (2) , and corespecific antibodies (3) . Wild type LPS is composed of one saccharide; MBP, mannose-binding protein; O-PS, O-polysaccharide. molecule of lipid A, one copy of a core oligosaccharide, and from none to more than 60 copies of the repeating O-polysaccharide (0-PS). Strains of Salmonella which lack the O-PS (rough phenotype) are generally nonpathogenic. These organisms are readily cleared from the circulation of experimental animals, are avidly ingested by phagocytes, and are directly killed by complement (4, 5) . Despite the adaptations ofSalmonella strains to avoid conventional host defenses, like antibody and complement, these organisms rarely cause life-threatening infections. This observation suggests that these organisms are effectively cleared by the host. We have recently shown that human mannose binding protein (MBP) can directly bind to wild type virulent Salmonella Montevideo that express a mannose-rich 0-PS. Interaction of native and recombinant MBP with this organism results in attachment, ingestion, and killing of MBP-opsonized bacteria by phagocytes in the absence of serum (6) .
MBPs were first isolated from the serum of rabbits (7) and subsequently found in the serum and liver of humans (8) (9) (10) and rodents (1 1, 12) . Analysis of human MBP, like its two rat homologues (13) , reveals that the molecule consists of a globular carbohydrate recognition domain, and a collagen-like region which is stabilized by a cysteine-rich NH2-terminal domain (8) . Initial experiments showed that human MBP bound yeast mannans (reviewed in reference 14) and were suggestive that MBP may have a role in host defense. Recently, we have shown that human MBP, which is an acute phase reactant (8) , can prevent in vitro infection of H9 lymphoblasts by HIV by binding to the high mannose glycans expressed on the envelope glycoprotein of HIV (15) . In addition, we have demonstrated that MBP can serve as an opsonin, and these findings underscore the role of MBP in first line host defense against mannose-rich pathogens (6) .
MBPs and C I q have similar overall organization, although there is no detectable homology between the collagenous or noncollagenous portions of the proteins (reviewed in references 13 and 16) . It therefore appeared likely that MBP would have a similar role to C Iq, namely binding to target molecules to activate Clr and Cl s and initiate classical complement pathway activation. In fact, Ikeda et al. (17) reported that MBP activated complement via the classical pathway to lyse mannan-coated erythrocytes. We set out to investigate whether MBP could enhance complement activation on virulent strains of Salmonella that are normally resistant to direct complement lysis.
In this report, we demonstrate that MBP-mediated deposition of complement on virulent Salmonella strains occurs via the alternative complement pathway. Surprisingly, the MBP (20) , and is phagocytosed by macrophages at a slow rate (21) . SH5770 is the least virulent (19), activates the alternative complement pathway efficiently (20) , and is readily phagocytosed (21) , whereas SH4340 occupies an intermediate position in all respects. Salmonella adelaide has a complete O-polysaccharide that contains no mannose. TV1 19, an Ra mutant ( Fig. 1 ) completely lacking O-polysaccharide, but having normal lipid A and a complete core polysaccharide with an exposed Nacetylglucosamine moiety, activates complement by the alternative pathway (22) . J5, an Rc mutant ( Fig. 1) , also lacks an O-polysaccharide side chain when grown in the absence of mannose and galactose. It activates the classical pathway independently of antibody (23, 24) .
Both TVl 19 and J5 are susceptible to complement-mediated serum bactericidal activity. All other Salmonella strains used in these experiments are resistant to serum lysis in nonimmune human serum.
Before each experiment the organisms were grown to mid-log phase in tryptic soy broth at 37°C with aeration, were washed twice in HBSS 20/1, and resuspended at OD 600 = 1.00 (1 X 109 organisms/ ml) in HBSS 20/1. Sera. Aliquots of normal human serum (NHS) collected from healthy, normal donors or from patients congenitally lacking complement components C7, C8, or C2 were stored at -70°C. Factor D-defi- used at a concentration of 5 X 109 bacteria/ml to adsorb a separate aliquot of ice-cold NHS. Adsorbed sera (ADS) stored at -70°C lost less than 20% of the starting hemolytic titer of C3. Antisera. Antibodies reactive with SH5770 were raised in rabbits according to described procedures (27) . A rabbit anti-human MBP antiserum was used as previously described (15) .
Mannose-binding protein. MBP was prepared as described previously (15) . The purified protein was characterized by electrophoresis on a 5-20% gradient SDS-polyacrylamide Laemmli gel (28) . Under nonreducing conditions, Coomassie blue staining showed MBP migrated as multimers of2 200 kD (Fig. 2 A) . In reducing conditions, MBP migrated as a single band at 30 kD (Fig. 2 B) , consistent with its known subunit structure.
For some experiments MBP was derivatized with biotin-N-hydroxysuccinimide ester (Behring Diagnostics, La Jolla, CA) suspended in NN-dimethylformamide (Sigma Chemical Co., St (32) . Functionally active human C3 was prepared by the procedure of Hammer et al. (33) with minor modifications, and was radiolabeled with '25I-Na using Iodobeads (Pierce Chemical Co.) according to manufacturer's instructions. Human factor D (25 Mg/ml in isotonic VBS, pH 7.4) was purified by a modification of the method of Volanakis et al. (34) . Factor B (4.3 mg/ml) was prepared using a minor modification of the method of Hammer et al. (33) . Just before use, factor B was diluted 1:10 in VBS 5 mM CaC12, pH 7.5. Guinea pig C2 was purchased from Cordis Laboratories, Miami, FL.
C3 nephritic factor was a gift from Dr. G. Tsokos, National Institutes of Health, Bethesda, MD. It was used at an IgG concentration of 5 Mg/ml in RPMI (Gibco Laboratories, Grand Island, NY).
Binding ofMBP to bacteria. MBP was allowed to bind to bacteria as described previously (6) . Briefly, 10 Mg/ml MBP was added to bacterial suspensions in HBSS 20/1, and the mixture was incubated for 60 min at 250C rotating end over end at [12] [13] [14] [15] (Fig. 4) , suggesting that even very small quantities of MBP circulating systemically could be important in the nonimmune host. This enhancement is observed in 2.5% serum, implying that MBP might also be important in tissues where quantities of complement components are scarce.
We then sought to competitively inhibit MBP activity with mannan, the complex carbohydrate composed of repeating mannose residues. Mannan added to the mixture of MBP and bacteria during the preincubation step decreased the augmentation of C3 binding by > 60% (Fig. 4) (Fig. 6) , MBP enhanced C3 deposition substantially. Addition of C2 to C2-deficient serum (Fig. 5) or Clq to Clqand factor D-deficient serum (Fig. 7) , did not augment complement deposition further. In contrast, the percent C3 bound to MBP-coated organisms was enhanced in a dose-dependent fashion by addition of factor D to Clq-and factor D-deficient serum (Fig. 6 ). In the absence of factor D, addition of C lq did not effect enhanced C3 binding through MBP (Fig. 7) . Increasing amounts of MBP added to C lq-and factor D-deficient serum did not restore C3 activation (Fig. 7) without added factor D. Thus, using at least three different conditions, we determined that MBP enhanced C3 deposition on SH5770 via the alternative complement pathway.
However, we performed the definitive test of alternative pathway mediation of this phenomenon. C3 deposition was tested using purified alternative complement pathway components in the absence of all natural antibodies, all classical pathway components, and all modulators of complement activation. As seen in Fig. 8 , SH5770 incubated in purified alternative pathway components in the presence of MBP bound more than twice as much C3 as in the absence of MBP. Clearly, this demonstrated a role for the alternative pathway in MBP-mediated complement deposition.
Activation ofC1 by MBP. In analogous fashion, the capacity of MBP to activate isolated classical pathway components was tested. Purified Cl q, Cl r, and C ls were reassociated to 0622 form the zymogen Cl. S. adelaide and SH5770 were preincubated in MBP or buffer then mixed with Cl-inhibitor and various combinations of purified, nonactivated, reassociated Cl subunits including '251-C ls. E. coli J5, which directly activates Cl, was used for the positive control. By densitometric scans, 65% of the total radiolabeled C ls was activated by E. coli J5 in the presence of Clq, C lr, and C ls, whereas only 13 and 17% activation was observed for S. adelaide or SH5770, respectively (Table II, Fig. 9 ). When these organisms were preincubated in MBP to bind MBP to their surfaces, then incubated with Clr, Cls, and '251-Cls in the absence of Clq, only 3% of Cls was cleaved by SH5770 and S. adelaide. J5 did not activate C Is at all. Nature ofC3 binding to MBP-coated bacteria. The form of C3 binding to bacterial constituents was compared in the presence and absence of MBP. When bacteria were incubated in serum with an intact alternative pathway, high molecular weight (> 150 kD), covalently bound, C3-acceptor complexes were evident in both the presence and absence of MBP (Figs. 10 and 11 A). Nonactivated C3 migrates in gels as the 120-kD alpha chain and the 75-kD beta chain (Fig. 1 1) . Upon methylamine treatment of MBP-coated bacteria that had been incubated in ADS, MgEGTA-treated ADS (Fig. 1 1) , C2-deficient, or factor D-deficient serum reconstituted with factor D (Fig.  10) , C3 was released from the large complexes and migrated as C3b (110 kD alpha chain) and iC3b (68 kD alpha' chain). The ratio of C3b to iC3b was -1:2 by densitometric scanning. In addition, a portion ofthe bonds formed between C3 and bacterial constituents in the presence of alternative pathway competent sera and MBP appeared to be resistant to the effects of ther organism was retained (Table III) . Thus there was no evidence suggesting that MBP was a prominent component of the high molecular weight complexes formed when MBPcoated organisms were incubated in serum.
Bactericidal activity. Serum bactericidal activity for SH5770 and S. adelaide was evaluated. Fig. 12 A shows doserelated killing of SH5770 preincubated in MBP then in increasing concentrations of ADS. In contrast, there was no killing of S. adelaide (A) or SH5771 (data not shown) presensi- tized with MBP. Strain SH5770 presensitized with MBP was killed equally well in ADS or EGTA-treated ADS (Fig. 12 B) . All strains multiplied in heat-inactivated serum whether or not they were preincubated in MBP. Preincubation in specific antisera similarly enhanced bactericidal activity for SH5770 (data not shown We initially anticipated that MBP would activate the classical complement pathway. MBP was reported to lyse mannan-coated sheep erythrocytes by activating the classical path-way (17) . In addition, MBP is structurally analogous, but bears no actual amino acid sequence homology to the classical complement pathway component C lq (40) . Despite structural similarities, MBP was unable to reconstitute the classical pathway (Fig. 7) when Clq was omitted. In addition, neither mannoserich SH5770 nor mannose-free S. adelaide activated significant amounts of Cl s in the presence of MBP, Cl r, and C ls. We considered briefly the possibility that MBP may activate complement via the unconventional Cl-bypass pathway (41, 42) . However, MBP-mediated complement fixation occurred in the absence of calcium, and therefore Cl -bypass was not considered further. Hence activity tested under the experimental conditions we used can be ascribed to alternative complement pathway activation on bacteria. Interestingly, in some experiments, MBP appeared to inhibit activation of C ls within zymogen Cl (Table II) and therefore it may be an activator of the alternative pathway and inhibitor of the classical pathway. Another acute phase reactant, C-reactive protein, activates the classical pathway and inhibits alternative pathway activation on Streptococcus pneumoniae by binding to phosphorylcholine residues in the pneumococcal cell wall (43) . Hence, MBP and C-reactive protein may be counter-regulatory acute phase reactant proteins.
MBP-mediated complement deposition on ordinarily serum resistant Salmonella strains results in significant bactericidal activity (Fig. 12) . Bactericidal activity in the presence of MBP is not simply a consequence of enhanced complement deposition (Joiner, K. A., and J. E. Schweinle, unpublished observations). In this respect, MBP functions analogously to bactericidal IgG for E. coli (44, 45) and Neisseria gonorrheae (39, 46) . In contrast to the results with bactericidal IgG and E. coli (47) , however, covalent complexes between C3 and MBP are not apparently responsible for the enhanced bactericidal activity. Nonetheless, our results indicate that MBP alters the nature of the C3 acceptor bond, resulting in an amide linkage between C3 and putative bacterial acceptor molecules. It is therefore possible that MBP alters the bacterial surface and allows access of C3 to bacterial outer membrane proteins, a possibility we are currently investigating.
In addition to its effects with S. montevideo SH5770, MBP also enhanced C3 deposition on the Ra mutant, S. typhimurium TV1 19 and changed a portion of the C3b-acceptor bonds from ester to amide linkages. The possibility was considered that MBP is the bactericidal Ra-reactive factor that binds to N-acetyl glucosamine and glycero-D-mannoheptose residues in LPS of Ra chemotype strains of Salmonella and Ra-like strains of other enterobacteria (48, 49) . Although the Ra-reactive factor and MBP have several common characteristics, the Ra-reactive factor activates the classical complement pathway (48 
